

2013-2014

Section 3: Summaries of Infectious Diseases

Respiratory Syncytial Virus

Table 3.57. Maximum Number of Monthly Doses of Palivizumab for Respiratory Syncytial Virus Prophylaxis	
Infants Eligible for a Maximum of 5 Doses	Infants Eligible for a Maximum of 3 Doses
Infants younger than 24 months of age with chronic lung disease and requiring medical therapy	Preterm infants with gestational age of 32 weeks, 0 days to 34 weeks, 6 days with at least 1 risk factor and born 3 months before or during RSV season.
Infants younger than 24 months of age and requiring medical therapy for congenital heart disease	
Preterm infants born at or before 31 weeks, 6 days of gestation	
Certain infants with neuromuscular disease or congenital abnormalities of the airways	

Section 3: Summaries of Infectious Diseases

Respiratory Syncytial Virus

Table 3.56. Palivizumab Prophylaxis for Infants and Young Children With Chronic Lung Disease of Prematurity or Congenital Heart Disease	
Geographic Location	Earliest Date for Initiation of 5 Monthly Doses
Southeast Florida	July 1
North central and southwest Florida	September 15
Most other areas of United States	November 1

2013-2014

Section 3: Summaries of Infectious Diseases

Respiratory Syncytial Virus

Table 3.5B.

Maximum Number of Palivizumab Doses for RSV Prophylaxis of Preterm Infants Without Chronic Lung Disease, on the Basis of Birth Date, Gestational Age, and Presence of Risk Factors (Shown for Geographic Areas Beginning Prophylaxis on November 1)

Month of Birth	Maximum No. of Doses for Season Beginning November 1		
	≤28 Weeks, 6 Days of Gestation and <12 Months of Age at Start of Season	29 Weeks, 0 Days Through 31 Weeks, 6 Days of Gestation and <6 Months of Age at Start of Season	32 Weeks, 0 Days Through 34 Weeks, 6 Days of Gestation and With Risk Factor ^a
November 1 –March 31 of previous RSV season	5 ^b	0 ^c	0 ^d
April	5	0 ^c	0 ^d
May	5	5	0 ^d
June	5	5	0 ^d
July	5	5	0 ^d
August	5	5	1 ^e
September	5	5	2 ^e
October	5	5	3 ^e
November	5	5	3 ^e
December	4	4	3 ^e
January	3	3	3 ^e
February	2	2	2 ^e
March	1	1	1 ^e

If infant is discharged from the hospital during RSV season, fewer doses may be required.

^a Risk factors: (1) infant attends child care; or (2) infant has sibling younger than 5 years of age.

^b Some of these infants may have received 1 or more doses of palivizumab in the previous RSV season if discharged from the hospital during that season; if so, they still qualify for up to 5 doses during their second RSV season.

^c Zero doses, because infant will be older than 6 months of age at start of RSV season.

^d Zero doses, because infant will be older than 90 days of age at start of RSV season.

^e On the basis of the age of patients at the time of discharge from the hospital, fewer doses may be required, because these infants will receive 1 dose every 30 days until they are 90 days of age.